MannKind

MannKind Net Debt / EBITDA

The Net Debt to EBITDA of MannKind (MNKD) as of Oct 28, 2026 is 10.24. In the previous year, Net Debt to EBITDA was 1.27 — a change of 704.60% (higher).

Net Debt / EBITDA

10.24

YoY

704.60%

Last updated:

Net Debt to EBITDA of MannKind is 2025 10.24 . Net Debt to EBITDA of MannKind was 2024 1.27 . It decreases by 704.60% higher compared to the previous year.

The MannKind Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
-0.40 USD
Jan 1, 2019
-1.64 USD
Jan 1, 2020
-1.15 USD
Jan 1, 2021
-2.76 USD
Jan 1, 2022
-3.17 USD
Jan 1, 2023
25.76 USD
Jan 1, 2024
1.27 USD
Jan 1, 2025
10.24 USD
The MannKind Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
10.24+704.60%
1.27-95.06%
25.76-911.62%
-3.17+15.01%
-2.76+139.93%
-1.15-30.01%
-1.64+307.93%
-0.40-62.77%
-1.08-157.94%
1.87-515.17%
-0.45-22.36%
-0.58-9.73%
-0.64-64.92%
-1.83-46.77%
-3.44+67.70%
-2.05+97.41%
-1.04+264.64%
-0.28-114.01%
2.03-10.00%
2.26—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MannKind Stock analysis

What does MannKind do? MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MannKind stock

Net Debt to EBITDA of MannKind is 10.24 in 2025.

Net Debt to EBITDA of MannKind changed from 1.27 to 10.24, representing a 704.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA MannKind since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's MannKind with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — MannKind

All Key Metrics — MannKind